Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab')(2) fragment rabies immunoglobulin (Favirab).

scientific article

Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab')(2) fragment rabies immunoglobulin (Favirab). is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1371/JOURNAL.PNTD.0000243
P932PMC publication ID2386244
P698PubMed publication ID18509475
P5875ResearchGate publication ID5331573

P50authorRuby DizonQ118382775
Marilyn E CrisostomoQ118382777
Hazel Z DytiocoQ118382778
Thelma M LaotQ118382779
P2093author name stringBeatriz P Quiambao
Dirk E Teuwen
P2860cites workIs injecting a finger with rabies immunoglobulin dangerous?Q36560046
Assessing the burden of human rabies in India: results of a national multi-center epidemiological surveyQ39754170
The incurable wound revisited: progress in human rabies prevention?Q40718615
A tale of two worlds: public health management decisions in human rabies preventionQ43218201
Efficacy of rabies immunoglobulins in an experimental post-exposure prophylaxis rodent modelQ47387628
A study of human rabies immune globulin manufactured by the Thai Red CrossQ74586102
Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccineQ77429475
Rabies post-exposure prophylaxis in malnourished children exposed to suspect rabid animalsQ81223506
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectrabies immunoglobulinQ4067112
PhilippinesQ928
rabiesQ39222
post-exposure prophylaxisQ1361206
P304page(s)e243
P577publication date2008-05-28
P1433published inPLoS Neglected Tropical DiseasesQ3359737
P1476titleRabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab')(2) fragment rabies immunoglobulin (Favirab).
P478volume2

Reverse relations

cites work (P2860)
Q41495590An addition to treatment options for avian influenza A H5N1?
Q90520682An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route
Q38708817Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens
Q33872166Bites from the same dog, different outcomes for two patients: a case report
Q35065696Factors associated with delay in post-exposure prophylaxis in bitten people
Q90137863Fatal outcomes following immunization errors as reported to the EudraVigilance: A case series
Q57926583Human rabies post exposure prophylaxis in Bhutan, 2005–2008: Trends and risk factors
Q38924824Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV.
Q60191963Intradermal rabies post-exposure prophylaxis can be abridged with no measurable impact on clinical outcome in Cambodia, 2003–2014
Q39374912Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines
Q41495598Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study
Q58093670Scoping decades of dog evidence: a scoping review of dog bite-related sequelae
Q42228728Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice
Q38997495Two decades of pharmacovigilance and clinical experience with highly purified rabies immunoglobulin F(ab')2 fragments
Q47222982Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biolog
Q54107517[Rabies].
Q92455760mRNA: A Novel Avenue to Antibody Therapy?